Linkedin
RLS logo_header
Linkedin

Submission of New Drug Application for Glecirasib announced

Dr. Yinxiang Wang, Chairman and CEO of Jacobio, said: “Since its establishment in 2015, Jacobio has been committed to develop the undruggable targets. Glecirasib’s NDA  submission is a milestone for the company and also marks that Jacobio will enter the commercialization stage. NDA submission is just the beginning. We will continue to explore the potential of glecirasib as a single agent and combination therapy in the fields of lung cancer, pancreatic cancer, colorectal cancer and multi-tumors basket to solve the actual clinical needs of more patients.

Read the full story on "Submission of New Drug Application for Glecirasib announced"

Share:

More News

FDA Granted Fast Track Designation for TER-2013 for HR+ve/HER2neg Breast Cancer

“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”

FDA Clears amendment to Open U.S. Enrollment in Ongoing Ph 2 THIO-101 Trial Expansion

“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two

ASCO 2026

Serplulimab Receives Positive CHMP Opinion for the Treatment of sqNSCLC

Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.